Drug Profile
PGT 121
Alternative Names: PGT121Latest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator Theraclone Sciences
- Developer Centre for the AIDS Programme of Research in South Africa; International AIDS Vaccine Initiative; The Ragon Institute of MGH, MIT and Harvard
- Class Antivirals; Cancer vaccines; Monoclonal antibodies
- Mechanism of Action HIV envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 03 Mar 2024 Efficacy data from a phase I/IIa trial in HIV infections presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 Session (CROI-2024)
- 02 May 2022 International AIDS Vaccine Initiative completes a phase I/IIa trial in HIV infections (Combination therapy) in USA (IV) (NCT03721510)
- 12 Feb 2022 Pharmacodynamics data from preclinical trials in HIV infection presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI-2022)